Paroxetine use during pregnancy and the risk of cardiac defects
- PMID: 27197980
- PMCID: PMC4972175
- DOI: 10.1111/bcp.12979
Paroxetine use during pregnancy and the risk of cardiac defects
Comment on
-
The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Br J Clin Pharmacol. 2016 Apr;81(4):589-604. doi: 10.1111/bcp.12849. Epub 2016 Jan 26. Br J Clin Pharmacol. 2016. PMID: 26613360 Free PMC article.
-
Meta-analysis requires independent observations and freedom from bias.Br J Clin Pharmacol. 2016 Jun;81(6):1191-3. doi: 10.1111/bcp.12898. Epub 2016 Mar 23. Br J Clin Pharmacol. 2016. PMID: 26845509 Free PMC article. No abstract available.
References
-
- Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta‐analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010; 88: 159–70. - PubMed
-
- Myles N, Newall H, Ward H, Large M. Systematic meta‐analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 2013; 47: 1002–12. - PubMed
-
- Bérard A. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence? Birth Defects Res A Clin Mol Teratol 2010; 88: 171–4. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
